Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada. Meanwhile, Accord has launched a Pelgraz pegfilgrastim pre-filled injector and patient app in the UK.

Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.

Accord Healthcare has garnered the first positive opinion recommending granting a pan-European marketing authorization for a generic version of rivaroxaban from the EMA’s CHMP. However, originator Bayer claims that no generic competition will be possible for another three years.

While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.